GB0525662D0 - Immunoglobulins - Google Patents

Immunoglobulins

Info

Publication number
GB0525662D0
GB0525662D0 GBGB0525662.3A GB0525662A GB0525662D0 GB 0525662 D0 GB0525662 D0 GB 0525662D0 GB 0525662 A GB0525662 A GB 0525662A GB 0525662 D0 GB0525662 D0 GB 0525662D0
Authority
GB
United Kingdom
Prior art keywords
immunoglobulins
antibodies
nogo
prophylaxis
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0525662.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0525662(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0525662.3A priority Critical patent/GB0525662D0/en
Publication of GB0525662D0 publication Critical patent/GB0525662D0/en
Priority to HK08113307.3A priority patent/HK1119720B/en
Priority to ES06830633T priority patent/ES2389380T3/es
Priority to HRP20120684TT priority patent/HRP20120684T1/hr
Priority to JP2008545009A priority patent/JP5015949B2/ja
Priority to PCT/EP2006/069737 priority patent/WO2007068750A2/en
Priority to DK06830633.1T priority patent/DK1960429T3/da
Priority to SI200631393T priority patent/SI1960429T1/sl
Priority to NZ569143A priority patent/NZ569143A/en
Priority to AU2006325228A priority patent/AU2006325228B2/en
Priority to BRPI0619855-4A priority patent/BRPI0619855A2/pt
Priority to CA2633501A priority patent/CA2633501C/en
Priority to PT06830633T priority patent/PT1960429E/pt
Priority to MYPI20082130A priority patent/MY149492A/en
Priority to PE2006001607A priority patent/PE20071099A1/es
Priority to KR1020087017348A priority patent/KR101355118B1/ko
Priority to EA200801343A priority patent/EA015536B1/ru
Priority to ARP060105524A priority patent/AR057239A1/es
Priority to UAA200807663A priority patent/UA96279C2/ru
Priority to EP20100162457 priority patent/EP2228391A3/en
Priority to TW095146890A priority patent/TWI378940B/zh
Priority to US12/097,279 priority patent/US8362208B2/en
Priority to EP06830633A priority patent/EP1960429B1/en
Priority to PL06830633T priority patent/PL1960429T3/pl
Priority to CN2006800529521A priority patent/CN101374863B/zh
Priority to JO2006457A priority patent/JO2795B1/en
Priority to MA31018A priority patent/MA30041B1/fr
Priority to NO20082699A priority patent/NO20082699L/no
Priority to ZA200805111A priority patent/ZA200805111B/xx
Priority to IL192086A priority patent/IL192086A0/en
Priority to CR10099A priority patent/CR10099A/es
Priority to ZA200906162A priority patent/ZA200906162B/en
Priority to CY20121100801T priority patent/CY1113094T1/el
Priority to US13/751,588 priority patent/US20130287781A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0525662.3A 2005-12-16 2005-12-16 Immunoglobulins Ceased GB0525662D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PL06830633T PL1960429T3 (pl) 2005-12-16 2006-12-14 Immunoglobuliny skierowane przeciwko nogo
CN2006800529521A CN101374863B (zh) 2005-12-16 2006-12-14 针对nogo的免疫球蛋白
KR1020087017348A KR101355118B1 (ko) 2005-12-16 2006-12-14 Ｎｏｇｏ에 유도되는 면역글로불린
UAA200807663A UA96279C2 (ru) 2005-12-16 2006-12-14 Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo
HRP20120684TT HRP20120684T1 (hr) 2005-12-16 2006-12-14 Imunglobulini protiv nogo
JP2008545009A JP5015949B2 (ja) 2005-12-16 2006-12-14 Ｎｏｇｏを標的とする免疫グロブリン
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo
DK06830633.1T DK1960429T3 (da) 2005-12-16 2006-12-14 Immunglobuliner rettet mod NOGO
SI200631393T SI1960429T1 (sl) 2005-12-16 2006-12-14 Imunoglobulini, usmerjeni proti NOGO
NZ569143A NZ569143A (en) 2005-12-16 2006-12-14 Immunoglobulins directed against NOGO
AU2006325228A AU2006325228B2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against NOGO
BRPI0619855-4A BRPI0619855A2 (pt) 2005-12-16 2006-12-14 região variável de cadeia pesada, anticorpo, composição farmacêutica, uso de um anticorpo, e, polinucleotìdeo
CA2633501A CA2633501C (en) 2005-12-16 2006-12-14 Immunoglobulins
PT06830633T PT1960429E (pt) 2005-12-16 2006-12-14 Imunoglobulinas dirigidas contra nogo
MYPI20082130A MY149492A (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo
PE2006001607A PE20071099A1 (es) 2005-12-16 2006-12-14 Inmunoglobulinas en el tratamiento de enfermedades neurologicas
HK08113307.3A HK1119720B (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo
EA200801343A EA015536B1 (ru) 2005-12-16 2006-12-14 Антитело или его фрагменты, связывающиеся с nogo-a человека, и применение антитела и фрагментов
ARP060105524A AR057239A1 (es) 2005-12-16 2006-12-14 Inmunoglobulinas
ES06830633T ES2389380T3 (es) 2005-12-16 2006-12-14 Inmunoglobulinas dirigidas contra NOGO
EP20100162457 EP2228391A3 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against Nogo
TW095146890A TWI378940B (en) 2005-12-16 2006-12-14 Immunoglobulins
US12/097,279 US8362208B2 (en) 2005-12-16 2006-12-14 Immunoglobulins
EP06830633A EP1960429B1 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo
JO2006457A JO2795B1 (en) 2005-12-16 2006-12-24 Immunoglobulins
ZA200805111A ZA200805111B (en) 2005-12-16 2008-06-11 Immunoglobulins directed against NOGO
MA31018A MA30041B1 (fr) 2005-12-16 2008-06-11 Immunoglobulines
NO20082699A NO20082699L (no) 2005-12-16 2008-06-11 Immunoglobuliner
IL192086A IL192086A0 (en) 2005-12-16 2008-06-12 Immunoglobulins directed against nogo
CR10099A CR10099A (es) 2005-12-16 2008-06-20 Inmunoglobulinas dirigidas contra nogo
ZA200906162A ZA200906162B (en) 2005-12-16 2009-09-04 Immunoglobulins directed against NOGO
CY20121100801T CY1113094T1 (el) 2005-12-16 2012-09-05 Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
US13/751,588 US20130287781A1 (en) 2005-12-16 2013-01-28 Immunoglobulins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Publications (1)

Publication Number Publication Date
GB0525662D0 true GB0525662D0 (en) 2006-01-25

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0525662.3A Ceased GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins

Country Status (30)

Country Link
US (2) US8362208B2 (https=)
EP (2) EP2228391A3 (https=)
JP (1) JP5015949B2 (https=)
KR (1) KR101355118B1 (https=)
CN (1) CN101374863B (https=)
AR (1) AR057239A1 (https=)
AU (1) AU2006325228B2 (https=)
BR (1) BRPI0619855A2 (https=)
CA (1) CA2633501C (https=)
CR (1) CR10099A (https=)
CY (1) CY1113094T1 (https=)
DK (1) DK1960429T3 (https=)
EA (1) EA015536B1 (https=)
ES (1) ES2389380T3 (https=)
GB (1) GB0525662D0 (https=)
HR (1) HRP20120684T1 (https=)
IL (1) IL192086A0 (https=)
JO (1) JO2795B1 (https=)
MA (1) MA30041B1 (https=)
MY (1) MY149492A (https=)
NO (1) NO20082699L (https=)
NZ (1) NZ569143A (https=)
PE (1) PE20071099A1 (https=)
PL (1) PL1960429T3 (https=)
PT (1) PT1960429E (https=)
SI (1) SI1960429T1 (https=)
TW (1) TWI378940B (https=)
UA (1) UA96279C2 (https=)
WO (1) WO2007068750A2 (https=)
ZA (2) ZA200805111B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
HRP20130699T1 (hr) * 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
PE20091829A1 (es) 2008-05-06 2009-12-12 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
WO2020250204A1 (ko) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. 신규 cthrc1에 특이적 항체 및 이의 용도
WO2021079002A2 (en) 2019-10-24 2021-04-29 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
EP4355782A1 (en) 2021-06-17 2024-04-24 Petmedix Ltd. Anti canine cd20 antibodies
MX2024004875A (es) 2021-10-21 2024-07-19 Petmedix Ltd Proteinas que comprenden en el dominio extracelular de p75ntr.
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
US20250340659A1 (en) 2022-02-09 2025-11-06 PetMedix Ltd. Therapeutic antibodies
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
AU2024217925A1 (en) 2023-02-09 2025-08-14 Zoetis Services Uk Limited Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
ATE275415T1 (de) 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
TW200801038A (en) 2008-01-01
CR10099A (es) 2008-09-22
US20130287781A1 (en) 2013-10-31
ES2389380T3 (es) 2012-10-25
TWI378940B (en) 2012-12-11
JP5015949B2 (ja) 2012-09-05
CN101374863A (zh) 2009-02-25
CA2633501C (en) 2015-03-31
EP1960429A2 (en) 2008-08-27
KR20080080644A (ko) 2008-09-04
PE20071099A1 (es) 2007-11-22
JO2795B1 (en) 2014-03-15
UA96279C2 (ru) 2011-10-25
ZA200805111B (en) 2009-12-30
EP2228391A2 (en) 2010-09-15
PL1960429T3 (pl) 2012-11-30
CY1113094T1 (el) 2016-04-13
EP2228391A3 (en) 2010-12-29
AU2006325228A1 (en) 2007-06-21
AR057239A1 (es) 2007-11-21
PT1960429E (pt) 2012-09-25
BRPI0619855A2 (pt) 2011-10-25
US8362208B2 (en) 2013-01-29
HRP20120684T1 (hr) 2012-09-30
CA2633501A1 (en) 2007-06-21
US20100221260A1 (en) 2010-09-02
ZA200906162B (en) 2010-05-26
IL192086A0 (en) 2008-12-29
CN101374863B (zh) 2013-05-29
MY149492A (en) 2013-09-13
KR101355118B1 (ko) 2014-02-06
JP2009519025A (ja) 2009-05-14
EA015536B1 (ru) 2011-08-30
WO2007068750A2 (en) 2007-06-21
EA200801343A1 (ru) 2008-12-30
EP1960429B1 (en) 2012-06-27
HK1119720A1 (en) 2009-03-13
NO20082699L (no) 2008-09-08
SI1960429T1 (sl) 2012-09-28
AU2006325228B2 (en) 2011-12-15
DK1960429T3 (da) 2012-09-24
MA30041B1 (fr) 2008-12-01
WO2007068750A3 (en) 2007-11-29
NZ569143A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
GB0525662D0 (en) Immunoglobulins
MY144612A (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
MX2010003574A (es) Anticuerpos il-23.
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE526987T1 (de) Dr5-antikörper und deren verwendung
EP1951319A4 (en) Chimeric immunoreceptor useful in treating human cancers
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200709817A (en) Platform antibody compositions
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
WO2007047112A3 (en) Anti-myostatin antibodies
ES2391382T8 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
TW200628473A (en) Novel heterocycles
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
TW200740808A (en) Inhibiteurs de proteines kinases
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
SI1838716T1 (sl) Olanzapin pamoat dihidrat

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)